AscellaHealth announces its strategic alliance with Optime Care to further enhance its ability to become a leader in Specialty Pharmacy (SP) services and establish a strong trajectory for growth. AscellaHealth’s comprehensive suite of services provides solutions for all industry segments, with support for payers to achieve cost-effective access and Life Sciences services including pre-commercialization and outsourced market access capabilities, wholesale, distribution and third-party logistics services, SP limited distribution drug (LLD) fulfillment with national reach and high-touch patient capabilities, and patient support/Hub services for Life Sciences.
AscellaHealth Forges Strategic Alliance with Optime Care: Expands Innovative Services for Specialty Pharmacy and Enhances Focus on Rare Diseases
“AscellaHealth is a premier partner in SP and healthcare services for improving medication access and optimizing outcomes for patients with complex, chronic conditions or rare diseases that require specialty medications and/or gene and cell therapies, offering services for all segments of the industry,” says Dea Belazi, president and CEO, AscellaHealth. “Our patient-centric approach is built upon proprietary technology processes for innovative programs and services designed to support pharmaceutical manufacturers in product launches and drug management programs, streamlined communications and coordination among providers and patients, and positive impact on the quality of life for our most vulnerable populations – people with specialty conditions and/ or rare diseases. This alliance ensures that branded specialty products are brought to market successfully, seamlessly accessed by patients, and the patient journey is optimized via clinical pull through programs and real time outcomes data. AscellaHealth’s unique solution set fosters a high level of patient satisfaction and brand loyalty, while enabling payers to realize cost savings in specialty spend.”
Michelle Hefley, co-founder, managing partner and chairman, Optime Care, adds, “This partnership is a powerful combination that brings together AscellaHealth’s specialty pharmacy solutions for all industry stakeholders with Optime Care’s strong understanding and focus on serving individuals with rare diseases. We share a commitment to a patient-first approach while concurrently serving the needs of Life Science companies to maximize therapeutic opportunities. This alignment will also help providers to better meet and coordinate care for their patients while enabling pharmacists to address an even broader range of disease states. Working together, our professional teams will optimize treatment, including specialty medications and cell/gene therapies, for rare disease communities.”
Optime Care, Inc. is a nationally recognized pharmacy, distribution and patient management organization offering a suite of comprehensive services tailored to maximize the therapeutic opportunities for the treatment of orphan and rare disorders. Our management team has previously partnered in the launch and management of more than 40 orphan products and programs and consistently implemented the best brand programs for the community. Our experience with small patient populations makes us uniquely qualified to help every stakeholder group impacted by these disorders. Optime Care has dual-accreditation from the Utilization Review Accreditation Commission (URAC) for compliance with specialty pharmacy and the Accreditation Commission for Health Care (ACHC) for specialty pharmacy services that demonstrate a commitment to providing quality care and services to consumers. https://www.optimecare.com/